S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
ASX:NXS

Next Science Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume86,564 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive NXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Next Science and its competitors with MarketBeat's FREE daily newsletter.


About Next Science

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site and post-operative infections. It has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University Clinical Research Institute, Southwest Regional Wound Care Center, University of Florida Department of Otolaryngology, and Jacksonville Center for Clinical Research. Next Science Limited has operations in the United States and Australia. The company was founded in 2012 and is headquartered in Chatswood, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.30 million
Book Value
A$0.08 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Next Science (ASX:NXS) Frequently Asked Questions

What stocks does MarketBeat like better than Next Science?

Wall Street analysts have given Next Science a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Next Science wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Next Science's key executives?

Next Science's management team includes the following people:
  • Ms. Judith Mitchell M.B.A., MD, CEO & Exec. Director
  • Dr. Matthew Myntti, Founder & CTO
  • Ms. Jacqueline Butler CA (ICAEW), Chief Financial Officer
  • Mr. Jon Swanson, Chief Operating Officer
  • Mr. Dustin Haines, Chief Commercial Officer
  • Ms. Gillian Maria Nairn, Company Sec.

What other stocks do shareholders of Next Science own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Next Science investors own include Abbott Laboratories (ABT), AbbVie (ABBV), Goldman Sachs Physical Gold ETF (AAAU), Argo Investments (ARG), Arcturus Therapeutics (ARCT), Appen (APX), Afterpay (APT), Advanced Micro Devices (AMD), Altium (ALU) and Alector (ALEC).

What is Next Science's stock symbol?

Next Science trades on the ASX under the ticker symbol "NXS."

How much money does Next Science make?

Next Science has a market capitalization of $0.00 and generates $6.30 million in revenue each year.

What is Next Science's official website?

The official website for Next Science is www.nextscience.com.

How can I contact Next Science?

The company can be reached via phone at 61 2 8607 5124.


This page was last updated on 10/17/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.